IDENTIFICATION OF A SPECIFIC HLA CLASS-II HAPLOTYPE STRONGLY ASSOCIATED WITH SUSCEPTIBILITY TO CYCLOSPORINE-DEPENDENT APLASTIC-ANEMIA

被引:113
作者
NAKAO, S
TAKAMATSU, H
CHUHJO, T
UEDA, M
SHIOBARA, S
MATSUDA, T
KANESHIGE, T
MIZOGUCHI, H
机构
[1] SHIONOGI BIOMED LABS,OSAKA,JAPAN
[2] TOKYO WOMENS MED COLL,DEPT HEMATOL,TOKYO 162,JAPAN
关键词
D O I
10.1182/blood.V84.12.4257.bloodjournal84124257
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hematopoietic function of some aplastic anemia (AA) patients is dependent on the administration of cyclosporine (CyA). To investigate whether certain HLA class II genes are associated with susceptibility to such CyA-dependent AA, we determined the HLA class II alleles of 59 AA patients treated with CyA, Among 26 patients successfully treated with CyA, 13 required a small dose of CyA to maintain stable hematopoiesis. Of these 13 AA patients, 10 shared an HLA class II haplotype of DRB1*1501-DQA1*0102-DQB1*0602. None of the 13 responders who obtained a sustained remission off CyA therapy possessed this haplotype. In the 10 patients who shared the HLA class II haplotype, single-strand conformation polymorphism analysis of each gene fragment of this haplotype failed to detect a polymorphism in the nucleotide sequence. When the AA patients were assessed for their likelihood to respond to CyA therapy, the response rate in patients with this haplotype (71%) was significantly higher than that of patients with another haplotype associated with HLA-DR2, DRB1*1502-DQA1*0103-DQB1*0601 (36%) and that of patients without HLA-DR2 (35%). These findings indicate that the CyA-dependent response of AA is closely related to an HLA class II haplotype of DRB1*1501-DQA1*0102-DQB1*0602 and suggest that, in AA patients with this haplotype, immune mechanisms play an important role in the pathogenesis of bone marrow failure. (C) 1994 by The American Society of Hematology.
引用
收藏
页码:4257 / 4261
页数:5
相关论文
共 19 条
[1]   CYCLOSPORINE TREATMENT FOR APLASTIC-ANEMIA - A CASE-REPORT DEMONSTRATING A 2ND RESPONSE TO 2ND EXPOSURE TO CYCLOSPORINE [J].
BERN, MM ;
ROBERTS, MS ;
YOBURN, D .
AMERICAN JOURNAL OF HEMATOLOGY, 1987, 24 (03) :307-309
[2]   FACTORS ASSOCIATED WITH EARLY REMISSION OF TYPE-I DIABETES IN CHILDREN TREATED WITH CYCLOSPORINE [J].
BOUGNERES, PF ;
CAREL, JC ;
CASTANO, L ;
BOITARD, C ;
GARDIN, JP ;
LANDAIS, P ;
HORS, J ;
MIHATSCH, MJ ;
PAILLARD, M ;
CHAUSSAIN, JL ;
BACH, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (11) :663-670
[3]  
FRICKHOFEN N, 1990, AM J PEDIAT HEMATOL, V12, P385
[4]  
GLUCKMAN E, 1992, BLOOD, V79, P2540
[5]  
HASHIMOTO M, IN PRESS TISSUE ANTI
[6]   POLYMERASE CHAIN-REACTION SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS OF POLYMORPHISM IN DPA1 AND DPB1 GENES - A SIMPLE, ECONOMICAL, AND RAPID METHOD FOR HISTOCOMPATIBILITY TESTING [J].
HOSHINO, S ;
KIMURA, A ;
FUKUDA, Y ;
DOHI, K ;
SASAZUKI, T .
HUMAN IMMUNOLOGY, 1992, 33 (02) :98-107
[7]  
Imanishi T, 1992, HLA 1991, P1065
[8]   IMMUNOSTIMULATORY EFFECTS OF DIFFERENT ANTILYMPHOCYTE GLOBULIN PREPARATIONS - A POSSIBLE CLUE TO THEIR CLINICAL EFFECT [J].
KAWANO, Y ;
NISSEN, C ;
GRATWOHL, A ;
SPECK, B .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 68 (01) :115-119
[9]   A SIMPLE AND RAPID METHOD FOR HLA-DQA1 GENOTYPING BY DIGESTION OF PCR-AMPLIFIED DNA WITH ALLELE SPECIFIC RESTRICTION ENDONUCLEASES [J].
MAEDA, M ;
MURAYAMA, N ;
ISHII, H ;
URYU, N ;
OTA, M ;
TSUJI, K ;
INOKO, H .
TISSUE ANTIGENS, 1989, 34 (05) :290-298
[10]   HLA-DR2 PREDICTS A FAVORABLE RESPONSE TO CYCLOSPORINE THERAPY IN PATIENTS WITH BONE-MARROW FAILURE [J].
NAKAO, S ;
YAMAGUCHI, M ;
SAITO, M ;
YASUE, S ;
SHIOBARA, S ;
MATSUDA, T ;
NITTA, M ;
SASAKI, M .
AMERICAN JOURNAL OF HEMATOLOGY, 1992, 40 (03) :239-240